Vivos Therapeutics, Inc. - VVOS STOCK NEWS

Vivos Therapeutics has announced the opening of The Vivos Institute in Denver, Colorado. This 15,000-square-foot training facility aims to significantly enhance education for healthcare providers on treating obstructive sleep apnea (OSA). The Institute can train 300 to 400 professionals daily, offering hands-on education about OSA and Vivos’ treatments. Key funding of over $500,000 in equipment was donated by dental and medical supply companies. The opening is part of Vivos' mission to improve awareness and treatment options for sleep-disordered breathing.

Vivos Therapeutics (NASDAQ: VVOS) announced results from a national study involving 74 adult patients with obstructive sleep apnea (OSA) treated with its FDA Class 1 DNA appliance. The study revealed that 28% of patients reported no remaining OSA symptoms post-treatment. Additionally, 82% showed improvement in their Apnea Hypopnea Index (AHI) scores, with 64% improving by at least one category. The average treatment lasted 14 months, and findings have been submitted to the FDA for 510k clearance. Vivos believes their technology may be a breakthrough for OSA treatment.

Vivos Therapeutics (NASDAQ: VVOS) announced positive results from an independent patient survey regarding its treatment for obstructive sleep apnea (OSA). Key findings show that 97% of patients achieved their desired outcomes with Vivos treatment, while 63% sought dentists' advice for solutions. The treatment typically lasts 12 to 24 months and addresses dental tissue anomalies linked to OSA, providing a non-invasive alternative to CPAP. The survey involved 123 patients and was executed by The EyeDeas Company in June 2021.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced the release of a new book by its Founder and Chief Medical Officer, Dr. G. Dave Singh, aimed at helping medical professionals understand craniofacial conditions affecting sleep health. The book, titled Pneumopedics and Craniofacial Epigenetics, explores the link between dentofacial anomalies and obstructive sleep apnea (OSA). Vivos’ technology offers a non-invasive treatment for mild-to-moderate OSA, now proven effective in over 17,000 patients. The book serves as a culmination of Dr. Singh's research and aims to advance understanding of innovative therapy options.

Vivos Therapeutics (NASDAQ: VVOS) reported its Q1 2021 financial results, revealing a revenue of $3.4 million, an 8% increase from Q1 2020. Gross profit rose by 11% to $2.7 million with a gross margin of 78%. However, net loss increased to $3.4 million from $2.6 million year-over-year. The company bolstered its finances with a follow-on offering generating $27.6 million in May. Recent developments include the launch of AireO2 software and VivoScore home testing services, along with the opening of Pneusomnia Centers aimed at enhancing treatment options for sleep disorders.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its first-quarter financial results for 2021 on May 17, 2021, after market close. A conference call is scheduled for the same day at 5:00 PM ET, where the company will discuss its financial performance and growth strategy. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA). Their Vivos System has been effective for over 15,000 patients worldwide through customized oral appliances.

Vivos Therapeutics, Inc. (VVOS) announced the closing of its public offering of 4,600,000 shares of common stock, including 600,000 additional shares underwriters purchased. The offering price was set at $6.00 per share, leading to gross proceeds of $27.6 million before expenses. Roth Capital Partners served as the sole book-running manager, while National Securities Corporation and Craig-Hallum Capital Group were co-managers. The SEC declared the registration statement effective on May 6, 2021, and the final prospectus was filed on May 10, 2021.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) announced the pricing of a follow-on public offering of 4,000,000 shares of its common stock at $6.00 per share, aiming for gross proceeds of $24 million before deductions. The offering includes a 45-day option for underwriters to buy an additional 600,000 shares. Roth Capital Partners is the sole book-running manager for the offering. The Securities and Exchange Commission (SEC) has declared effective registration statements, and a final prospectus will be filed with the SEC. Investors are encouraged to read the prospectus for complete information.

Vivos Therapeutics (NASDAQ: VVOS) announced the appointment of Dr. Mimi Guarneri as Medical Director of Clinical Education, effective April 1, 2021. Dr. Guarneri is a renowned Integrative Cardiologist, board-certified in multiple specialties, and a founder of The Academy of Integrative Health and Medicine. Her role will focus on promoting the Vivos Medical Integration Division, leveraging her expertise to enhance physician awareness of Vivos’ innovative treatments for obstructive sleep apnea (OSA). The company aims to improve patient outcomes with its non-invasive Vivos System, already utilized by over 1,200 dentists worldwide.